Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
January 20, 2026 17:31 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo.,…
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
January 20, 2026 17:20 ET | Source: Tempest Therapeutics BRISBANE, Calif., Jan.…
AlphaTON Capital Signs Definitive Agreement to Launch First Fully Privacy-Preserving AI Agents to Telegrams Billion Users
New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital (Nasdaq:…
WISeKey, WISeSat.Space and SEALSQ To Host Trust and Convergence 2026: The Year of Quantum Security Discussions During Flagship Davos Gathering
January 20, 2026 01:00 ET | Source: Wisekey International Holding Ltd. WISeKey,…
BionIT Labs Launches Adams Hand for Humanoids and Service Robots
Image by BionIT Labs SOLETO, Italy, Jan. 19, 2026 (GLOBE NEWSWIRE) --…
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific…
Valneva Provides Update on Chikungunya Vaccine IXCHIQ
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of…
![Metabo Drops 2026 [Latest Update]: Is It Legit? Liquid Delivery Science, Ingredient Research, and Informed Consumer Analysis](https://i3.wp.com/fixedagency.com/wp-content/uploads/2026/01/Metabo-Drops-2026-Latest-Update-Is-It-Legit-Liquid-Delivery-Science-Ingredient-Research-and-Informed-Consumer-Analysis.jpg?w=420&resize=420,280&ssl=1 "Metabo Drops 2026 [Latest Update]: Is It Legit? Liquid Delivery Science, Ingredient Research, and Informed Consumer Analysis")
Metabo Drops 2026 [Latest Update]: Is It Legit? Liquid Delivery Science, Ingredient Research, and Informed Consumer Analysis
NEW YORK, NY, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article…
Immuron Reports Continued Sales Growth
Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior…
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for…
